Updates in IDH-Wildtype Glioblastoma

Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021 WHO CNS5 classification has further stressed the importance of molecular signatures in diagnosis although therapeutic breakthroughs are still lacking. In this review article, updates on the current and novel ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Melhem, Jawad M., Detsky, Jay, Lim-Fat, Mary Jane, Perry, James R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9154038/
https://www.ncbi.nlm.nih.gov/pubmed/35641844
http://dx.doi.org/10.1007/s13311-022-01251-6
Descripción
Sumario:Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021 WHO CNS5 classification has further stressed the importance of molecular signatures in diagnosis although therapeutic breakthroughs are still lacking. In this review article, updates on the current and novel therapies in IDH-wildtype GBM will be discussed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13311-022-01251-6.

Ejemplares similares